Multimorbidity in osteoarthritis

Multimorbidity in osteoarthritis

This review is focused on the issue of terminology in patients with multiple coexisting diseases in modern clinical practice. We articulate that multimorbidity is one of the leading problems in the field of public healthcare and that the treatment of these patients demands an integral approach deriv...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. A. Taskina, L. I. Alekseeva, N. G. Kashevarova, A. M. Lila, E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2022-07-01
Series:	Научно-практическая ревматология
Subjects:	multimorbidity osteoarthritis pleiotropic effects sysadoa alflutop
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3178
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term multicenter observational study of the drug Alflutop in Russia: use in patients with knee osteoarthritis (report 4)
by: E. A. Taskina, et al.
Published: (2024-08-01)

Multimorbidity in osteoarthritis and pleiotropic effects of slow-acting symptomatic drugs. Resolution of the multidisciplinary International Expert Council
by: V. I. Mazurov, et al.
Published: (2023-10-01)

Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners
by: A. M. Lila, et al.
Published: (2021-10-01)

Analysis of the therapeutic benefits of symptomatic slow acting drugs in osteoarthritis: emphasis on structural-modifying action
by: I. B. Belyaeva, et al.
Published: (2021-12-01)

Multicenter Longitudinal Observational Study Pharmaceuticals Alflutop in Russia (message 2)
by: A. M. Lila, et al.
Published: (2023-08-01)

Alflutop Russian longitudinal multicentre observational study: preliminary results (message 1)
by: A. M. Lila, et al.
Published: (2023-04-01)

Evaluation of the efficiency and safety of combined therapy with a symptomatic sustained-release drug and hyaluronic acid versus monotherapy with hyaluronic acid in patients with knee osteoarthritis
by: K. A. Berdyugin, et al.
Published: (2020-09-01)

Alflutop in osteoarthritis therapy
by: G. V. Lukina, et al.
Published: (2004-06-01)

Symptomatic delayed-acting drugs (SYSADOA): new applications
by: A. M. Lila, et al.
Published: (2022-05-01)

Alflutop clinical efficacy assessment in osteoarthritis (two-years study)
by: V. N. Chodyrev, et al.
Published: (2003-02-01)

CHONDROPROTECTIVE DRUG ALFLUTOP IN THE TREATMENT OF OSTEOARTHRITIS
by: G V Lukina, et al.
Published: (2001-04-01)

Clinical cases of SYSADOA use in complex conservative therapy of patients with knee osteoarthritis
by: O. A. Kaplunov, et al.
Published: (2021-09-01)

Critical evaluation of the current role of SYSADOA in the management of osteoarthritis (literature review)
by: V.V. Cherniavskyi, et al.
Published: (2024-06-01)

A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens
by: E. P. Sharapova, et al.
Published: (2020-03-01)

The use of symptomatic slow-acting drugs for osteoarthritis of the joints of the hands: Accent on microcirculation parameters
by: A. S. Trofimova, et al.
Published: (2024-03-01)

A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 1: Evaluation of the efficacy of the drug in different treatment regimens
by: L. I. Alekseeva, et al.
Published: (2019-09-01)

Evaluation of the efficacy and safety of bioactive concentrate from small sea fish in elderly patients with knee osteoarthritis
by: E. V. Usova, et al.
Published: (2021-02-01)

Pharmacological therapy in patients with osteoarthritis and metabolic disorders: focus on diacerein
by: O.V. Kuryata, et al.
Published: (2025-03-01)

Development of a verified osteoarthritis risk scale based on a cross-sectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients
by: I. Yu. Torshin, et al.
Published: (2023-04-01)

Results of a prospective 6-year observational study of the efficacy and safety of a bioactive concentrate of small marine fish in senile patients with knee osteoarthritis and multimorbidity
by: M. V. Letaeva, et al.
Published: (2021-08-01)

From misconceptions to reasonable osteoarthritis patients therapy
by: O. A. Shavlovskaya, et al.
Published: (2023-07-01)

A MULTICENTER, BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFET OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHRITIS. REPORT 2: THE ASSESSMENT OF THE STRUCTURE-MODIFYING EFFECT OF THE DRUG
by: L. I. Alekseeva, et al.
Published: (2014-06-01)

Evaluation of efficacy and adherence to treatment of patients with osteoarthritis with structure-modifying drug of SYSADOA group
by: I. G. Zolkornyaev
Published: (2024-05-01)

Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist's view)
by: A. S. Dukhanin
Published: (2018-06-01)

The place of nonsteroidal anti-inflammatory drugs in the current osteoarthritis guidelines
by: E. A. Taskina, et al.
Published: (2020-05-01)

THE CONCEPT OF MULTIMORBIDITY IN RHEUMATOLOGIC PRACTICE
by: A. V. Gordeev, et al.
Published: (2014-09-01)

Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis
by: E. P. Sharapova, et al.
Published: (2021-08-01)

Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment
by: L. I. Alekseeva, et al.
Published: (2019-05-01)

Factors associated with knee pain at early stages of osteoarthritis
by: A. R. Khalmetova, et al.
Published: (2025-06-01)

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

Features of the course and treatment of low back pain in patients with reduced bone mineral density
by: N. M. Shuba, et al.
Published: (2020-09-01)

Efficacy and safety of diacerein in patients with knee osteoarthritis
by: L. I. Alekseeva, et al.
Published: (2017-09-01)

MULTICENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFECT OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHROSIS. COMMUNICATION 1. EVALUATION OF THE SYMPTOM-MODIFYING EFFECT OF THE DRUG
by: Lyudmila Ivanovna Alekseeva, et al.
Published: (2013-12-01)

RISK FACTORS OF THE KNEE OSTEOARTHRITIS PROGRESSION
by: N. G. Kashevarova, et al.
Published: (2014-10-01)

Expression of genes related to glucose metabolism and joint destruction in the development of diabetes mellitus in patients with osteoarthritis
by: E. V. Chetina, et al.
Published: (2019-03-01)

Clinical and instrumental characteristics of osteoarthritis in hyperuricemia
by: E. A. Taskina, et al.
Published: (2024-10-01)

IMPROVING THE METHODOLOGY OF CONTINUOUS MEDICAL EDUCATION IN THE CONTEXT OF ARTERIAL HYPERTENSION TREATMENT
by: A. L. Vertkin, et al.
Published: (2013-10-01)

Pleiotropic effects of statins. Are there opportunities to explain of the phenomenon?
by: I. A. Latfullin, et al.
Published: (2015-12-01)

EVALUATION OF THE EFFICACY AND SAFETY OF A GLYCOSAMINOGLYCAN-PEPTIDE COMPLEX IN THE TREATMENT OF KNEE OSTEOARTHRITIS IN PATIENTS WITH PREVIOUS INEFFICIENCY OF SLOW-RELEASE ORAL ANTI-INFLAMMATORY DRUGS (THE MULTICENTER OPEN-LABEL STUDY PRIMULA: USE OF RUMALON® WITH INITIALLY SMALL SUCCESS IN THE TREATMENT OF OSTEOARTHRITIS)
by: A. E. Karateev, et al.
Published: (2018-03-01)

Pharmacotherapy of pain in musculoskeletal diseases: evolution and revolution of views
by: O. A. Shavlovskaya, et al.
Published: (2022-08-01)